by admin | Dec 2, 2019 | Clinical Trials
BAN2401 is a humanized monoclonal antibody that is the result of a strategic research alliance between BioArctic and Eisai. BAN2401 has a unique binding profile and selectively binds to and eliminates soluble, toxic amyloid-beta aggregates (protofibrils) that are...
by admin | Dec 2, 2019 | Clinical Trials
TauRx has reportedunexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer’s...
by admin | Nov 18, 2019 | Clinical Trials
Dragonfly Therapeutics, a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, announced that the first patient was dosed in a Phase 1/2 study of DF1001 at The University of Texas MD Anderson Cancer Center in...
by admin | Oct 8, 2019 | Clinical Trials
The narcolepsy drug, developed by Irish company Jazz Pharmaceuticals, has a lower salt content than the current treatment Xyrem, making it more suitable for patients at risk of cardiovascular disease. In a 200-patient phase III trial that finished in July, Jazz...
by admin | Sep 27, 2019 | Clinical Trials
Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, announced initiation of a Phase 1 open label clinical...
